Articles From: FBR to Host Digital Media Thought Leaders Conference to FDA Approves Cytori U.S. Pivotal Scleroderma Trial


ARLINGTON, Va., Oct.
Sign-up for FBR to Host Digital Media Thought Leaders Conference investment picks
ARLINGTON, Va., Oct.
Sign-up for FBR to Report Third Quarter 2014 Financial Results investment picks
2014/11/4
LONDON , November 4, 2014 /PRNewswire/ -- Fiat Chrysler Automobiles N.V. announces that the Company's Chief Executive Officer has exercised his stock options pursuant to the equity incentive plan entitling him to purchase 6,250,000 common shares of FCA and 6,250,000 shares of CNH Industrial N.V. ("CNHI") at the aggregate price of €13.37 for one FCA share and one CNHI share.
Sign-up for FCA - Exercise of Stock Options investment picks
2014/10/29
LONDON , October 29, 2014 /PRNewswire/ -- The Board of Directors of Fiat Chrysler Automobiles N.V. (NYSE: FCAU) ("FCA") announced that in connection with FCA's implementation of a capital plan appropriate to support the Group's long-term success, it has authorized the separation of Ferrari S.p.A. ("Ferrari") from FCA.
Sign-up for FCA Announces Board Intention to Spin Off Ferrari S.p.A. investment picks
2014/12/12
LONDON , December 12, 2014 /PRNewswire/ -- Fiat Chrysler Automobiles N.V. (NYSE: FCAU) ("FCA") announced today that the underwriters of its previously announced offering of common shares and mandatory convertible securities due 2016 have exercised in full their options to purchase from FCA an additional 13 million common shares and U.S. $375 million in aggregate notional amount of mandatory convertible securities.
Sign-up for FCA Announces Exercise of Underwriters' Option to Purchase Additional Common Shares and Mandatory Convertible Securities investment picks
2014/12/4
LONDON , December 4, 2014 /PRNewswire/ -- Fiat Chrysler Automobiles N.V. (NYSE: FCAU) ("FCA") announced today that it has launched an offering of 87 million common shares, nominal value €0.01 per share, consisting of common shares currently held by FCA as treasury shares and additional common shares that FCA intends to issue to replenish the share capital canceled in accordance with applicable law following the exercise by Fiat S.p.A. ("Fiat") shareholders of cash exit rights under Italian law in connection with the cross-border merger of Fiat into FCA.
Sign-up for FCA Announces Launch of Offering of Common Shares and Offering of Mandatory Convertible Securities investment picks
LONDON , Oct.
Sign-up for FCA Announces Management Change investment picks
2014/10/29
LONDON , October 29, 2014 /PRNewswire/ -- The Board of Directors of Fiat Chrysler Automobiles N.V. (NYSE: FCAU) ("FCA") today announced that it has authorized the offer and sale of FCA common shares and mandatory convertible securities in offerings to be registered with the U.S. Securities and Exchange Commission.
Sign-up for FCA Board Authorizes Capital Transactions investment picks
2014/10/29
LONDON , October 29, 2014 /PRNewswire/ -- The Board of Directors of Fiat Chrysler Automobiles N.V. (NYSE: FCAU) ("FCA") today announced that in connection with its discussions regarding capital planning to support the Group's 2014-2018 Business Plan, the Board confirmed FCA's intention to eliminate any contractual terms limiting the free flow of capital among members of the Group.
Sign-up for FCA Board Confirms Intentions on Capital Structure investment picks
2014/10/29
FCA third-quarter revenues up 14% to EUR23.6 billion and EBIT up 7% at EUR0.9 billion.
Sign-up for FCA Board of Directors' Meeting: Third Quarter 2014 Results investment picks
2014/12/16
LONDON , December 16, 2014 /PRNewswire/ -- Fiat Chrysler Automobiles N.V. (NYSE: FCAU) ("FCA") announced today that it has completed the sale of 100 million common shares, nominal value €0.01 per share, and U.S. $2,875 million in aggregate notional amount of its 7.875% mandatory convertible securities due 2016.
Sign-up for FCA Closes Offering of Common Shares and Offering of Mandatory Convertible Securities investment picks
2014/12/11
LONDON , December 11, 2014 /PRNewswire/ -- The press has reported certain rumors suggesting that Ferrari S.p.A. would be considering moving its fiscal residence outside Italy .
Sign-up for FCA Denies Rumors on Intent to Move the Tax Residence of Ferrari S.p.A. Outside Italy investment picks
2014/12/10
LONDON , Dec.
Sign-up for FCA prices offering of common shares and offering of mandatory convertible securities investment picks
2015/1/21
AUBURN HILLS, Mich.
Sign-up for FCA US LLC Will Host a Full-Year and Fourth-Quarter 2014 Financial Results Analyst Call and Webcast on Feb. 3 investment picks
FCB Financial Holdings, Inc. (NYSE:FCB) (the "Company") today announced financial results for the third quarter of 2014.
Sign-up for FCB Financial Holdings, Inc. Reports Third Quarter 2014 Financial Results investment picks
FCB Financial Holdings, Inc. (NYSE:FCB) today announced that it will release its fourth quarter 2014 financial results on Thursday, January 29, 2015 after close of market, and management will host a conference call at 5:00 p.m. Eastern Time that same day.
Sign-up for FCB Financial Holdings, Inc. Sets Earnings Release and Conference Call Date for Fourth Quarter 2014 Results investment picks
FCB Financial Holdings, Inc. (NYSE:FCB) (the "Company") today announced it will present at the Bank of America Merrill Lynch 2014 Banking & Financial Services Conference in New York City on Wednesday, November 12, 2014, at 9:40 a.m. Eastern Time.
Sign-up for FCB Financial Holdings, Inc. to Present at Bank of America Merrill Lynch 2014 Banking & Financial Services Conference investment picks
By Gautham Nagesh Chairman Tom Wheeler hopes changes allow consumers to buy channels a la carte The Federal Communications Commission Friday proposed new regulations on companies that provide subscription video services over the Internet, a move to give the companies access to more TV programming and allow them to compete with cable and satellite.
Sign-up for FCC proposes rules for online video services providers investment picks
Cerus Corporation (NASDAQ: CERS) today announced that the U.S. Food and Drug Administration (FDA) has accepted Cerus’ clinical protocol to make the INTERCEPT Blood System for plasma available under an Investigational Device Exemption (IDE) for treatment of convalescent plasma collected from Ebola disease survivors for passive immune therapy.
Sign-up for FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma investment picks
2015/1/12
By Friedrich Geiger BERLIN--The U.S. Food and Drug Administration has paved the way for the production of additional drugs at a Fresenius SE (FRE.XE) plant in New York state after the authorities there had detected flaws at the facility some years ago, the German healthcare company said Monday.
Sign-up for FDA Allows Fresenius to Make New Drugs at Plant in US investment picks
PHOENIX and VANCOUVER, British Columbia, Dec.
Sign-up for FDA Approves a Safer Way to Administer Vaccines investment picks
2014/12/19
By Peter Loftus AbbVie's Viekira Pak, a cocktail of several drugs, cured more than 90% of most common form of hepatitis C U.S. regulators on Friday approved AbbVie Inc.'s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.
Sign-up for FDA approves AbbVie's hepatitis treatment investment picks
This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need THOUSAND OAKS, Calif.
Sign-up for FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy investment picks
Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (AHA), a very rare and potentially life-threatening acute bleeding disorder.
Sign-up for FDA Approves Baxter’s OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A investment picks
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE®) Immunotherapy to be Approved by the FDA BLINCYTO (Blinatumomab) for Injection Will be Available as a 35 mcg Single use Vial THOUSAND OAKS, Calif.
Sign-up for FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia investment picks
By Ron Winslow U.S. regulators Monday approved Bristol-Myers Squibb Co.'s Opdivo for advanced skin cancer, the latest drug to reach the market in the emerging field of cancer immunotherapy.
Sign-up for FDA approves Bristol-Myers's skin cancer treatment Opdivo investment picks
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that the Center for Biologics Evaluation and Research (CBER), a division of the U.S. Food and Drug Administration (FDA), has given final approval to its application for an Investigational Device Exemption (IDE) to begin a pivotal trial (the “STAR trial”) to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma.
Sign-up for FDA Approves Cytori U.S. Pivotal Scleroderma Trial investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: FBR to Host Digital Media Thought Leaders Conference to FDA Approves Cytori U.S. Pivotal Scleroderma Trial
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent